Objective: The purpose of this study was to evaluate the utility of US for identifying and characterizing lesions detected on molecular breast imaging (MBI).
Methods: A retrospective single-institution review was performed of patients with MBI studies with subsequent US for abnormal MBI findings between January 1, 2015, and September 30, 2021. Medical records, imaging, and histopathology were reviewed. The reference standard was histopathology and/or imaging follow-up. Associations among MBI findings, the presence of an US correlate, and histopathology were evaluated by Fisher exact tests.
Results: The 32 lesions detected on MBI in 25 patients were evaluated by US, and 19 lesions had an US correlate (19/32, 59%). Mass uptake was more likely to have an US correlate (11/13, 85%; P = .02) than nonmass uptake (7/19, 37%), and mass uptake was more likely to be malignant (5/13, 38%; P = .01). Of the 13 lesions without an US correlate, 5 were evaluated and subsequently biopsied by MRI (2 high-risk lesions and 3 benign lesions). Follow-up MBIs demonstrated stability/resolution for 5 lesions in 4 patients at 6 months or longer. Three patients had no further imaging.
Conclusion: Mass lesions identified on MBI were more likely to have an US correlate and were more likely to be malignant than nonmass lesions.
Keywords: MRI; US; breast cancer; molecular breast imaging.
© Society of Breast Imaging 2024. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].